BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21898661)

  • 21. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
    Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
    Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.
    Fan C; Zhang J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2018 Oct; 143(8):1935-1942. PubMed ID: 29726012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
    Figueiredo JC; Haile RW; Bernstein L; Malone KE; Largent J; Langholz B; Lynch CF; Bertelsen L; Capanu M; Concannon P; Borg A; Børresen-Dale AL; Diep A; Teraoka S; Torngren T; Xue S; Bernstein JL
    Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study.
    Stovall M; Smith SA; Langholz BM; Boice JD; Shore RE; Andersson M; Buchholz TA; Capanu M; Bernstein L; Lynch CF; Malone KE; Anton-Culver H; Haile RW; Rosenstein BS; Reiner AS; Thomas DC; Bernstein JL;
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1021-30. PubMed ID: 18556141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Machine learning on genome-wide association studies to predict the risk of radiation-associated contralateral breast cancer in the WECARE Study.
    Lee S; Liang X; Woods M; Reiner AS; Concannon P; Bernstein L; Lynch CF; Boice JD; Deasy JO; Bernstein JL; Oh JH
    PLoS One; 2020; 15(2):e0226157. PubMed ID: 32106268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SNP-SNP interactions between DNA repair genes were associated with breast cancer risk in a Korean population.
    Han W; Kim KY; Yang SJ; Noh DY; Kang D; Kwack K
    Cancer; 2012 Feb; 118(3):594-602. PubMed ID: 21751184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The spectrum of ATM missense variants and their contribution to contralateral breast cancer.
    Broeks A; Braaf LM; Huseinovic A; Schmidt MK; Russell NS; van Leeuwen FE; Hogervorst FB; Van 't Veer LJ
    Breast Cancer Res Treat; 2008 Jan; 107(2):243-8. PubMed ID: 17393301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical radiation, family history of cancer, and benign breast disease in relation to breast cancer risk in young women, USA.
    Hill DA; Preston-Martin S; Ross RK; Bernstein L
    Cancer Causes Control; 2002 Oct; 13(8):711-8. PubMed ID: 12420949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
    Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
    Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations.
    McDuff SGR; Bellon JR; Shannon KM; Gadd MA; Dunn S; Rosenstein BS; Ho AY
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1373-1382. PubMed ID: 33545302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
    Einarsdóttir K; Rosenberg LU; Humphreys K; Bonnard C; Palmgren J; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
    Breast Cancer Res; 2006; 8(6):R67. PubMed ID: 17132159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus.
    Loizidou MA; Michael T; Neuhausen SL; Newbold RF; Marcou Y; Kakouri E; Daniel M; Papadopoulos P; Malas S; Hadjisavvas A; Kyriacou K
    Breast Cancer Res Treat; 2009 Jun; 115(3):623-7. PubMed ID: 18553220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline Variants in DNA Repair Genes, Diagnostic Radiation, and Risk of Thyroid Cancer.
    Sandler JE; Huang H; Zhao N; Wu W; Liu F; Ma S; Udelsman R; Zhang Y
    Cancer Epidemiol Biomarkers Prev; 2018 Mar; 27(3):285-294. PubMed ID: 29263185
    [No Abstract]   [Full Text] [Related]  

  • 37. The MRN protein complex genes: MRE11 and RAD50 and susceptibility to head and neck cancers.
    Ziółkowska-Suchanek I; Mosor M; Wierzbicka M; Rydzanicz M; Baranowska M; Nowak J
    Mol Cancer; 2013 Sep; 12(1):113. PubMed ID: 24079363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variants in DNA double-strand break repair genes and breast cancer susceptibility.
    Kuschel B; Auranen A; McBride S; Novik KL; Antoniou A; Lipscombe JM; Day NE; Easton DF; Ponder BA; Pharoah PD; Dunning A
    Hum Mol Genet; 2002 Jun; 11(12):1399-407. PubMed ID: 12023982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-center screening of mutations in the ATM gene among women with breast cancer - the WECARE Study.
    Berstein JL; Concannon P; Langholz B; Thompson WD; Bernstein L; Stovall M; Thomas DC;
    Radiat Res; 2005 Jun; 163(6):698-9. PubMed ID: 16044499
    [No Abstract]   [Full Text] [Related]  

  • 40. Carcinogen-induced DNA double strand break repair in sporadic breast cancer.
    Zhang C; Naftalis E; Euhus D
    J Surg Res; 2006 Sep; 135(1):120-8. PubMed ID: 16650867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.